Entries of Körner, Silvia on the publication server
 | Up a level |
Number of items: 2.
2022
Livingstone, Elisabeth, Zimmer, Lisa, Hassel, Jessica C., Fluck, Michael, Eigentler, Thomas K., Loquai, Carmen, Haferkamp, Sebastian 
, Gutzmer, Ralf, Meier, Friedegund , Mohr, Peter, Hauschild, Axel, Schilling, Bastian, Menzer, Christian , Kiecker, Felix, Dippel, Edgar, Roesch, Alexander, Ziemer, Mirjana, Conrad, Beate, Körner, Silvia, Windemuth-Kieselbach, Christine, Schwarz, Leonora, Garbe, Claus, Becker, Jürgen C., Schadendorf, Dirk, Livingstone, Elisabeth, Zimmer, Lisa, Hassel, Jessica C., Fluck, Michael, Eigentler, Thomas K., Loquai, Carmen, Haferkamp, Sebastian, Gutzmer, Ralf, Meier, Friedegund, Mohr, Peter, Hauschild, Axel, Schilling, Bastian, Menzer, Christian, Kiecker, Felix, Dippel, Edgar, Roesch, Alexander, Ziemer, Mirjana, Conrad, Beate, Körner, Silvia, Simon, Jan-Christoph, Herbst, Rudolf A., Berking, Carola, Utikal, Jochen, Sell, Sabine, Martens, Uwe M., Terheyden, Patrick, Stadler, Rudolf, Windemuth-Kieselbach, Christine, Schwarz, Leonora, Garbe, Claus, Becker, Jürgen C. and Schadendorf, Dirk
(2022)
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
The Lancet 400 (10358), pp. 1117-1129.
Fulltext not available.
, Gutzmer, Ralf, Meier, Friedegund , Mohr, Peter, Hauschild, Axel, Schilling, Bastian, Menzer, Christian , Kiecker, Felix, Dippel, Edgar, Roesch, Alexander, Ziemer, Mirjana, Conrad, Beate, Körner, Silvia, Windemuth-Kieselbach, Christine, Schwarz, Leonora, Garbe, Claus, Becker, Jürgen C., Schadendorf, Dirk, Livingstone, Elisabeth, Zimmer, Lisa, Hassel, Jessica C., Fluck, Michael, Eigentler, Thomas K., Loquai, Carmen, Haferkamp, Sebastian, Gutzmer, Ralf, Meier, Friedegund, Mohr, Peter, Hauschild, Axel, Schilling, Bastian, Menzer, Christian, Kiecker, Felix, Dippel, Edgar, Roesch, Alexander, Ziemer, Mirjana, Conrad, Beate, Körner, Silvia, Simon, Jan-Christoph, Herbst, Rudolf A., Berking, Carola, Utikal, Jochen, Sell, Sabine, Martens, Uwe M., Terheyden, Patrick, Stadler, Rudolf, Windemuth-Kieselbach, Christine, Schwarz, Leonora, Garbe, Claus, Becker, Jürgen C. and Schadendorf, Dirk
(2022)
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
The Lancet 400 (10358), pp. 1117-1129.
Fulltext not available.
2020
Zimmer, Lisa, Livingstone, Elisabeth, Hassel, Jessica C., Fluck, Michael, Eigentler, Thomas, Loquai, Carmen, Haferkamp, Sebastian, Gutzmer, Ralf, Meier, Friedegund, Mohr, Peter, Hauschild, Axel, Schilling, Bastian, Menzer, Christian, Kieker, Felix, Dippel, Edgar, Rösch, Alexander, Simon, Jan-Christoph, Conrad, Beate, Körner, Silvia, Windemuth-Kieselbach, Christine, Schwarz, Leonora, Garbe, Claus, Becker, Jürgen C., Schadendorf, Dirk, Berking, Carola, Herbst, Rudolf A., Martens, Uwe M., Sell, Sabine, Stadler, Rudolf, Terheyden, Patrick and Utikal, Jochen
(2020)
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
The Lancet 395 (10236), pp. 1558-1568.
Fulltext not available.